Finecure partners with innovators to bring complex generics and Novel Drug Delivery Systems to market through flexible out-licensing and Product-to-Product (P2P) co-development. Partners gain access to a ready-to-file dossier pipeline, a DSIR-approved R&D centre that provides a secure environment for intellectual property, and the manufacturing scale to take a molecule from concept to commercial supply - with development risk shared.
Surface the ready-to-file dossier pipeline, which currently appears only as a sentence on the Regulatory Compliance page: "Turnkey in-licensing opportunities are available, backed by ready-to-file dossiers." That is a proposition an importer understands immediately and most Indian manufacturer sites do not offer. It deserves a heading, not a clause.
Distinguish the two directions explicitly, because they attract different partners: out-licensing from Finecure to a partner's market, and in-licensing where Finecure takes a partner's product into India. The current page implies both and states neither.
Leverage a ready-to-file dossier pipeline. Out-licensing for proprietary formulations and specialized ranges, with full regulatory support for global filings.
Combine our DSIR-approved R&D with your molecular insight. P2P collaborations share the risk and reward of developing challenging molecules.
Alliances that combine Finecure’s manufacturing scale (five blocks, 80,000+ domestic outlets) with global technology for long-term market penetration.
Intellectual property is secured under OECD data-integrity guidelines, with R&D and manufacturing on 21 CFR Part 11 compliant systems - shared data encrypted, logged, and protected.